-
-
-
-
-
-
-
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 3c, provides guidance
-
-
-
-
-
-
-
MKT Capital Issues Statement Regarding Aurinia’s Disappointing First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aurinia, Stronghold, Lilium, and Li-Cycle and Encourages Investors to Contact the Firm
-
1,219,296 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

